Legal & General Group Plc purchased a new position in Penumbra, Inc. (NYSE:PEN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 64,912 shares of the company's stock, valued at approximately $20,496,000. Legal & General Group Plc owned about 0.16% of Penumbra as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Penumbra in the 2nd quarter worth $25,000. Larson Financial Group LLC raised its position in shares of Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company's stock valued at $26,000 after buying an additional 82 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Penumbra by 2,700.0% in the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company's stock valued at $26,000 after acquiring an additional 81 shares during the last quarter. Motiv8 Investments LLC bought a new position in shares of Penumbra in the 4th quarter valued at about $27,000. Finally, Keating Financial Advisory Services Inc. purchased a new position in Penumbra in the second quarter worth about $31,000. Hedge funds and other institutional investors own 88.88% of the company's stock.
Wall Street Analyst Weigh In
PEN has been the topic of a number of recent research reports. Wall Street Zen upgraded Penumbra to a "hold" rating in a research report on Saturday, May 9th. Evercore reissued an "outperform" rating and set a $320.00 target price on shares of Penumbra in a research report on Monday, July 6th. Weiss Ratings restated a "hold (c)" rating on shares of Penumbra in a report on Friday, July 17th. Royal Bank Of Canada restated a "sector perform" rating and issued a $374.00 price target on shares of Penumbra in a research report on Thursday, June 11th. Finally, Zacks Research raised shares of Penumbra from a "strong sell" rating to a "hold" rating in a research note on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $367.07.
Check Out Our Latest Analysis on Penumbra
Penumbra Price Performance
PEN opened at $321.58 on Friday. The business has a fifty day moving average of $320.71 and a 200 day moving average of $326.86. The stock has a market cap of $12.67 billion, a P/E ratio of 79.01, a PEG ratio of 1.99 and a beta of 0.70. The company has a quick ratio of 3.86, a current ratio of 5.75 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41.
Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing analysts' consensus estimates of $1.16 by ($0.28). The business had revenue of $390.05 million during the quarter, compared to analysts' expectations of $389.64 million. Penumbra had a return on equity of 10.50% and a net margin of 10.67%.The business's revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.86 EPS. As a group, sell-side analysts anticipate that Penumbra, Inc. will post 5.02 EPS for the current year.
Penumbra Profile
(
Free Report)
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
Further Reading
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Penumbra, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.
While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
